Yi Wang, Peng Luo, Ping Chen, Guochen Luo, Fujun Wu, Chong Wang, Jin Li, Yi Zhang, Xin Wang
{"title":"Trigger Point Injection: A Therapeutic Propellant for Myofascial Pain Syndromes.","authors":"Yi Wang, Peng Luo, Ping Chen, Guochen Luo, Fujun Wu, Chong Wang, Jin Li, Yi Zhang, Xin Wang","doi":"10.1177/19373341251364757","DOIUrl":null,"url":null,"abstract":"<p><p>Myofascial pain syndromes, stemming from trigger points within the muscles, represent a prevalent cause of localized or generalized pain in clinical practice. They have a high incidence rate and currently lack specific curative methods. Trigger point injection therapy is the most popular clinical approach, focusing primarily on these trigger points. Injectable drugs like glucose, normal saline, local anesthetics, botulinum toxin type A, steroid preparations, and platelet-rich plasma are available for this purpose. This treatment is advantageous due to its low cost and minimally invasive nature, showing promising results in early clinical use. However, the lack of consensus on the optimal injectable substance presents a significant challenge in clinical practice. This article reviews the progress in clinical research on trigger point injection therapy and drug efficacy, along with precautions for drug administration in managing myofascial pain syndrome. It aims to offer fresh perspectives for future studies and establish a theoretical foundation for treating and caring for myofascial pain syndrome.</p>","PeriodicalId":23134,"journal":{"name":"Tissue Engineering. Part B, Reviews","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tissue Engineering. Part B, Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/19373341251364757","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
Abstract
Myofascial pain syndromes, stemming from trigger points within the muscles, represent a prevalent cause of localized or generalized pain in clinical practice. They have a high incidence rate and currently lack specific curative methods. Trigger point injection therapy is the most popular clinical approach, focusing primarily on these trigger points. Injectable drugs like glucose, normal saline, local anesthetics, botulinum toxin type A, steroid preparations, and platelet-rich plasma are available for this purpose. This treatment is advantageous due to its low cost and minimally invasive nature, showing promising results in early clinical use. However, the lack of consensus on the optimal injectable substance presents a significant challenge in clinical practice. This article reviews the progress in clinical research on trigger point injection therapy and drug efficacy, along with precautions for drug administration in managing myofascial pain syndrome. It aims to offer fresh perspectives for future studies and establish a theoretical foundation for treating and caring for myofascial pain syndrome.
期刊介绍:
Tissue Engineering Reviews (Part B) meets the urgent need for high-quality review articles by presenting critical literature overviews and systematic summaries of research within the field to assess the current standing and future directions within relevant areas and technologies. Part B publishes bi-monthly.